Search Results - "ROWE, PAUL"

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation by Busse, William W, Kraft, Monica, Rabe, Klaus F, Deniz, Yamo, Rowe, Paul J, Ruddy, Marcella, Castro, Mario

“…Asthma is a complex respiratory disease that varies in severity and response to treatment. Several asthma phenotypes with unique clinical and inflammatory…”
Get full text

Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study by Wechsler, Michael E, Ford, Linda B, Maspero, Jorge F, Pavord, Ian D, Papi, Alberto, Bourdin, Arnaud, Watz, Henrik, Castro, Mario, Nenasheva, Natalia M, Tohda, Yuji, Langton, David, Cardona, Guido, Domingo, Christian, Park, Hae Sim, Chapman, Kenneth R, Mao, Xuezhou, Zhang, Yi, Khan, Asif H, Deniz, Yamo, Rowe, Paul J, Kapoor, Upender, Khokhar, Faisal A, Mannent, Leda P, Ruddy, Marcella, Laws, Elizabeth, Amin, Nikhil, Hardin, Megan

“…Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term…”
Get full text

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma by Bacharier, Leonard B, Maspero, Jorge F, Katelaris, Constance H, Fiocchi, Alessandro G, Gagnon, Remi, de Mir, Ines, Jain, Neal, Sher, Lawrence D, Mao, Xuezhou, Liu, Dongfang, Zhang, Yi, Khan, Asif H, Kapoor, Upender, Khokhar, Faisal A, Rowe, Paul J, Deniz, Yamo, Ruddy, Marcella, Laws, Elizabeth, Patel, Naimish, Weinreich, David M, Yancopoulos, George D, Amin, Nikhil, Mannent, Leda P, Lederer, David J, Hardin, Megan

“…In this randomized, controlled, phase 3 trial involving children between the ages of 6 and 11 years with uncontrolled moderate-to-severe asthma, those who…”
Get full text

Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma by Papadopoulos, Nikolaos G., Szefler, Stanley J., Bacharier, Leonard B., Maspero, Jorge F., Domingo, Christian, Fiocchi, Alessandro, Lee, Jason K., Daizadeh, Nadia, Lederer, David J., Hardin, Megan, Gall, Rebecca, Djandji, Michel, Siddiqui, Shahid, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background Cytokines, such as interleukins (IL)‐4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human…”
Get full text

Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma by Weinstein, Steven F., Katial, Rohit, Jayawardena, Shyamalie, Pirozzi, Gianluca, Staudinger, Heribert, Eckert, Laurent, Joish, Vijay N., Amin, Nikhil, Maroni, Jaman, Rowe, Paul, Graham, Neil M.H., Teper, Ariel

“…Dupilumab, an anti–IL-4 receptor α mAb, inhibits IL-4/IL-13 signaling, key drivers of type 2/TH2 immune diseases (eg, atopic/allergic disease). In a pivotal,…”
Get full text

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis by Wechsler, Michael E., Klion, Amy D., Paggiaro, Pierluigi, Nair, Parameswaran, Staumont-Salle, Delphine, Radwan, Amr, Johnson, Robert R., Kapoor, Upender, Khokhar, Faisal A., Daizadeh, Nadia, Chen, Zhen, Laws, Elizabeth, Ortiz, Benjamin, Jacob-Nara, Juby A., Mannent, Leda P., Rowe, Paul J., Deniz, Yamo

“…Transient increases in blood eosinophil counts have been observed in dupilumab clinical trials. To assess eosinophil counts and eosinophilia-related…”
Get full text

Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study by Tohda, Yuji, Nakamura, Yoichi, Fujisawa, Takao, Ebisawa, Motohiro, Msihid, Jerome, Djandji, Michel, Ortiz, Benjamin, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Ishida, Masato, Arima, Kazuhiko

“…Safety and efficacy data for dupilumab beyond 1 year are lacking for patients from Japan with moderate-to-severe asthma. The TRAVERSE open-label extension…”
Get full text

Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline by Bourdin, Arnaud, Virchow, J. Christian, Papi, Alberto, Lugogo, Njira L., Bardin, Philip, Antila, Martti, Halpin, David M.G., Daizadeh, Nadia, Djandji, Michel, Ortiz, Benjamin, Jacob-Nara, Juby A., Gall, Rebecca, Deniz, Yamo, Rowe, Paul J.

“…Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3…”
Get full text

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis by Busse, William W, Wenzel, Sally E, Casale, Thomas B, FitzGerald, J Mark, Rice, Megan S, Daizadeh, Nadia, Deniz, Yamo, Patel, Naimish, Harel, Sivan, Rowe, Paul J, Graham, Neil M H, O'Riordan, Thomas, Pavord, Ian D

“…Fractional exhaled nitric oxide (FeNO) has potential as a prognostic biomarker in asthma, but its prognostic value among other recognised indicators is…”
Get full text

Disease Burden and Unmet Need in Eosinophilic Esophagitis by Bredenoord, Albert J., Patel, Kiran, Schoepfer, Alain M., Dellon, Evan S., Chehade, Mirna, Aceves, Seema S., Spergel, Jonathan M., Shumel, Brad, Deniz, Yamo, Rowe, Paul J., Jacob-Nara, Juby A.

“…Eosinophilic esophagitis (EoE) is a chronic, progressive, type 2 inflammatory disease of increasing prevalence, characterized by symptoms of dysphagia and…”
Get full text

Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook by Rabe, Klaus F, Rennard, Stephen, Martinez, Fernando J, Celli, Bartolome R, Singh, Dave, Papi, Alberto, Bafadhel, Mona, Heble, Jigna, Radwan, Amr, Soler, Xavier, Jacob Nara, Juby A, Deniz, Yamo, Rowe, Paul J

“…Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous, progressive inflammatory airway disease associated with a significant impact on…”
Get full text

Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial by Sher, Lawrence D, Wechsler, Michael E, Rabe, Klaus F, Maspero, Jorge F, Daizadeh, Nadia, Mao, Xuezhou, Ortiz, Benjamin, Mannent, Leda P, Laws, Elizabeth, Ruddy, Marcella, Pandit-Abid, Nami, Jacob-Nara, Juby A, Gall, Rebecca, Rowe, Paul J, Deniz, Yamo, Lederer, David J, Hardin, Megan

“…Many patients with severe asthma require chronic corticosteroid treatment to maintain asthma control. Are the reduction in oral corticosteroid (OCS) use and…”
Get full text

Impact of dupilumab across seasons in patients with type 2, uncontrolled, moderate-to-severe asthma by Peters, Anju T., Sagara, Hironori, Corren, Jonathan, Domingo, Christian, Altincatal, Arman, Soler, Xavier, Pandit-Abid, Nami, Crikelair, Nora, Rowe, Paul J., Jacob-Nara, Juby A., Deniz, Yamo

“…Seasonal variability could influence asthma exacerbations. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin…”
Get full text

The Global-and Globalist-Roots of Evangelical Action by Rowe, Paul S.

“…Contemporary conservative populists across the world enjoy significant support among evangelicals. However, their embrace of isolationism, mercantilism,…”
Get full text

Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study by Phipatanakul, Wanda, Vogelberg, Christian, Bacharier, Leonard B., Dell, Sharon, Altincatal, Arman, Gall, Rebecca, Ledanois, Oliver, Sacks, Harry, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background The phase 3 VOYAGE (NCT02948959) and open‐label extension EXCURSION (NCT03560466) studies evaluated dupilumab in children (6–11 years) with…”
Get full text

BASELINE CHARACTERISTICS AND COEXISTING TYPE 2 INFLAMMATORY DISEASES OF PATIENTS WITH ASTHMA INITIATING DUPILUMAB IN A REAL-WORLD SETTING: THE RAPID REGISTRY by LUGOGO, NJIRA L, PETERS, ANJU T, CÔTÉ, ANDRÉANNE, HILBERG, OLE, HEFFLER, ENRICO, MUNOZ, XAVIER, VINGE, INES, MANSUR, ADEL, NAGASE, HIROYUKI, SHAO, LIYANG, GALL, REBECCA, DE PRADO GOMEZ, LUCIA, JACOB-NARA, JUBY A, SACKS, HARRY, ROWE, PAUL J, DENIZ, YAMO, BOURDIN, ARNAUD

Get full text

Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP by Bachert, Claus, Khan, Asif H., Fokkens, Wytske J., Hopkins, Claire, Gevaert, Philippe, Han, Joseph K., Hellings, Peter W., Lee, Stella E., Msihid, Jérôme, Nash, Scott, Sacks, Harry, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…[Display omitted] Responder analyses of SINUS phase 3 study data have shown clinically meaningful improvements across multiple outcomes of treatment of chronic…”
Get full text

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST by Maspero, Jorge F., FitzGerald, John Mark, Pavord, Ian D., Rice, Megan S., Maroni, Jaman, Rowe, Paul J., Pirozzi, Gianluca, Amin, Nikhil, Ruddy, Marcella, Graham, Neil M. H., Teper, Ariel, Hardin, Megan

Get full text

Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52 by Bachert, Claus, Khan, Asif H., Lee, Stella E., Hopkins, Claire, Peters, Anju T., Fokkens, Wytske, Praestgaard, Amy, Radwan, Amr, Nash, Scott, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.

“…Background This post hoc analysis of the international SINUS‐24/‐52 trials (NCT02912468/NCT02898454) aimed to assess dupilumab efficacy in patients with severe…”
Get full text

Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma by Pavord, Ian D., Deniz, Yamo, Corren, Jonathan, Casale, Thomas B., FitzGerald, J. Mark, Izuhara, Kenji, Daizadeh, Nadia, Ortiz, Benjamin, Johnson, Robert R., Harel, Sivan, Djandji, Michel, Goga, Ledia, Crikelair, Nora, Rowe, Paul J., Busse, William W.

“…FeNO may have a role as both a prognostic and predictive biomarker in combination with eosinophils for assessing responsiveness to some biological therapies…”
Get full text